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Abstract
Background: Accumulation of amyloid-b (Ab) peptide in the brain is thought to play a key pathological role in
Alzheimer’s disease. Many pharmacological targets have therefore been proposed based upon the biochemistry of
Ab, but not all are equally tractable for drug discovery.
Results: To search for novel targets that affect brain Ab without causing toxicity, we screened mouse brain
samples from 1930 novel gene knock-out (KO) strains, representing 1926 genes, using Ab ELISA assays. Although
robust Ab lowering was readily apparent in brains from a BACE1 KO strain, none of the novel strains exhibited
robust decreases in brain Ab, including a GPR3 KO strain, which had previously been proposed as an Ab target.
However, significantly increased Ab was observed in brain samples from two KO strains, corresponding to genes
encoding the glycosylphosphatidylinositol mannosyl transferase PIGZ and quinolinate phosphoribosyltransferase
(QPRT).
Conclusions: Thus, gene ablations that are permissive for mouse survival and that also have a robust effect on Ab
levels in the brain are rare.
Background
The amyloid hypothesis states that Alzheimer’ disease
(AD) is caused by accumulation of toxic forms of the
amyloid-b (Ab) peptide in the brain. Ab is a secreted
peptide formed through consecutive proteolytic clea-
vages of the amyloid precursor protein (APP) by the
b-site APP cleaving enzyme (BACE1), which releases the
N-terminal end of Ab,a n dg-secretase, which releases a
range of Ab C-terminal ends resulting in Ab peptides of
typically 37-42 amino acids in length. The predominant
form of Ab has 40 amino acid residues, and is denoted
Ab40, whereas the disease-associated Ab42 has two
additional C-terminal residues [1]. On the basis of the
biochemistry and pathology of Ab, many molecular tar-
gets have been proposed for inhibition of Ab accumula-
tion, aggregation, or the toxic effects of Ab [2-5]. Thus,
Ab formation can be targeted directly via inhibition of
BACE1 or g-secretase, or indirectly via inhibition of
pathways that regulate the activity of these proteases.
Indirect regulation of BACE1 involves a particularly
wide range of mechanisms, recently reviewed in detail
by Hunt and Turner [6], and of potential pathological
relevance because of the increased BACE1 activity
observed in the AD brain [7-10]. In brief, BACE1 activ-
ity can be regulated through a variety of molecular tar-
gets involved in cytokine signaling [11,12], hypoxia
[13,14], oxidative stress [15], energy deprivation [16],
intracellular trafficking and maturation [17-19], and gly-
cosylphosphatidylinositol (GPI) anchor metabolism
[20-22]. Indirect targets have also been reported to regu-
late g-secretase activity, including GSK3a [23], Rac1
GTPase [24], casein kinase I [25] and the G-protein
coupled receptor GPR3 [26]. In addition, competition
between the proteasome and g-secretase for the C-term-
inal BACE1-derived APP processing intermediate can
affect Ab levels in cell cultures [27].
APP itself is a direct target of small molecule modula-
tors of Ab production [28,29], and can be targeted
indirectly via the prolyl isomerase Pin1 [30], sphingoli-
pid metabolism [31], reticulon/Nogo proteins [32,33],
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microdomain switching [36]. APP-mediated changes in
Ab can also result from increased cleavage of the non-
amyloidogenic a-site of APP, thus competing with BACE1
for the available APP substrate, as reviewed by Fahrenholz
[ 3 7 ] .I nb r i e f ,m e t a l l o p r o t e a s e ss u c ha sA D A M 1 0[ 3 8 ]
carry out a-site cleavage, which can be activated via multi-
ple targets, including retinoic acid receptor [39,40] liver-
X-receptor, muscarinic acytylcholine receptor M1 [41,42],
G protein coupled receptor PAC1 [43], protein kinase C
[44,45], and low cholesterol [46].
In addition to the regulation of Ab biosynthesis, Ab
clearance is also regulated. Clearance of Ab combines
several mechanisms, including the LXR/ABCA1/APOE
pathway [47], degradation by endoproteases, reviewed
by Nalivaeva et al. 2008 [48], transport across the
blood-brain barrier involving RAGE and LRP1 receptors,
reviewed by Deane and Zlokovic [49], lymphatic drai-
nage, reviewed by Weller et al. [50] and microglial
uptake of Ab [51,52]. Indirect regulation of Ab clearance
has also been reported, for example, modulation of
neprilysin endoprotease by somatostatin receptor signal-
ing [53], and enhanced Ab proteolysis dependent on the
ApoE isoform [54]. In addition, resveratrol, a polyphenol
in red wine, has been proposed to enhance Ab clearance
via the proteasome [55].
Thus, it seems reasonable to anticipate numerous
molecular targets capable of altering Ab levels, and that
at least some of the targets should be relevant to Ab
formation in the brain. The ideal target should have the
potential for robust brain Ab-lowering without toxicity,
and characteristics that facilitate development of inhibi-
tors. We therefore took the approach of direct screening
of brain Ab levels in novel mouse gene knock out (KO)
strains, an approach that has the dual advantages of
providing evidence both for target effectiveness in
Ab-lowering and for target safety. Given that even opti-
mized drug molecules may not be capable of 100% abla-
tion of target function, we were most interested in
finding KO strains with 50% or more reduction in brain
Ab levels. A total of 1930 viable homozygous gene abla-
tions, representing 1926 genes, were tested. Surprisingly,
none of these gene ablations exhibited robust decreases
in Ab. In addition, we also evaluated GPR3 KO mice,
recently proposed as an Ab target [26], but found no
overall effect on levels of brain Ab. In contrast, signifi-
cantly increased brain Ab was detected in samples from
two mouse KO strains corresponding to the proteins
PIGZ and QPRT, respectively involved in GPI anchor
biosynthesis and the kynurenine pathway of tryptophan
degradation. Thus, while the mouse KO screen did not
directly identify novel targets for lowering Ab,i td i d
suggest a limited number of biochemical pathways that
might be significant for regulation of brain Ab levels
in vivo, and that gene ablations causing a robust effect
on brain Ab are rare.
Results
A screen of mouse KO strains for altered brain Ab levels
Mouse knock-out (KO) strains were generated over a
period of four years, and brain samples were collected
and assayed during this time on an ongoing basis. Fig-
ure 1 outlines the screening procedure. Using four
homozygous individuals per KO strain, brain Ab40
levels were determined using the left brain halves, and
selected KO strains were chosen, based on potentially
altered Ab40 levels, for further Ab determinations using
the corresponding right brain halves. For KO strains in
which Ab median values were consistently altered, the
identity of the gene KO was then revealed in order to
make a decision on further studies. A summary of the
1926 genes by gene class is shown in Table 1, note that
the sample is non-random and includes only strains in
which the homozygous KO was viable.
The results of the primary Ab40 screen for 1930 dif-
ferent KO strains are illustrated in Figure 2. The data
were well approximated by a normal distribution
(Shapiro-Wilk’s test p > 0.05) with standard deviation of
10%, indicating that a KO strain exhibiting a robust
decrease of 50% would have been detected with 98%
probability. The false positive error rate for observing a
KO strain more than three standard deviations below
the mean was estimated to be 0.13%. In spite of the
high probability of detecting Ab40 lowering, none of the
novel 1930 KO strains appeared to lower Ab40 by an
amount that could be unequivocally distinguished from
the general distribution. In contrast, samples from two
KO strains exhibited approximately 100% increased
Ab40, which, at greater than 10 sd above baseline level,
were far outside the general distribution (Figure 2). The
false positive error rate associated with 10 sd is less
than 6.7E-16. The genes corresponding to these two KO
strains were PIGZ, encoding an enzyme required for 4th
mannose side chain addition to the GPI protein anchor
precursor, and QPRT, encoding quinolinate phosphori-
bosyltransferase, an enzyme of the kynurenine pathway
of tryptophan degradation (see Discussion).
For 77 selected KO strains, particularly those exhibit-
ing a median Ab value more than 2 sd below control
values, repeat Ab40 assays, and in some cases Ab42
assays, were carried out using the right brain half
(Figure 3 panels A and B). For most of these 77 KO
strains, the small changes in average Ab40 levels were
similar in magnitude to the assay variability, and it was
therefore no surprise that very few of the results con-
firmed consistent changes of Ab40 in the right brain
halves. Consistent with this, there was no significant dif-
f e r e n c eb e t w e e nt h eA b values in the right and left
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Page 2 of 12brain halves. (The mean difference was 3.23%, and a
paired t-test yielded a t-value of 0.98, with 76 degrees of
freedom, and a P-value of 0.33.) Nevertheless, the two
KO strains that exhibited the greatest Ab40-lowering in
both left and right brain assays were UBE2R2 and
ADRM1, both involved in the ubiquitin/proteasome sys-
tem (UPS, see Discussion). In contrast, the robust aver-
age Ab40 increases exhibited in the PIGZ KO and
QPRT KO were readily confirmed in the right brain
halves (Figure 3 panels A and B). Changes in mean
Ab42 were consistent with the changes in Ab40 for the
PIGZ, QPRT, UBE2R2 and ADRM1 KO mice (Figure 3
panel C). In the case of the ADRM1 KO, all the Ab
values were tightly grouped at about 30% lowering,
whereas PIGZ, QPRT and UBE2R2 KO strains exhibited
considerable individual variability in Ab levels. For
PIGZ, the difference in Ab40 values between the left
and right brain assays possibly reflected the different
extraction procedures used; CHAPS extraction for the
left and guanidine/SPE extraction for the right half (see
Materials and Methods). However, this difference was
not statistically significant (Table 2).
Ablation of GPR3 did not affect total brain Ab levels
Deletion of the orphan G protein coupled receptor
GPR3 has recently been reported to decrease hippocam-
pal Ab40 and Ab4 2i nA P Pt r a n s g e n i cm i c eb ya
mechanism that involves the regulation of g-secretase
[26]. We engineered a GPR3 KO strain and carried out
Ab assays using extracts from sagittal brain halves (see
Materials and Methods). Young mice showed no signifi-
cant differences in brain Ab42, Ab40 or Ab1-x levels
between mice carrying the homozygous or heterozygous
KO genotypes and homozygous wild type siblings
Figure 1 Outline of screening tiers.A b40 in four brain samples (sagittal left halves) from 1930 different mouse KO strains were determined. Of
these, 77 KO strains were selected for further Ab40 determinations, and in some cases Ab42 determinations, of the corresponding right brain
halves. The gene information for four of the KO strains is reported in the current study. Prioritization for possible drug discovery efforts was then
based upon multiple considerations, including the robustness of Ab inhibition, tractability of the target for small molecule inhibition, and
relevance of the target to AD.
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cant difference in brain Ab40 and Ab42 levels between
the GPR3 KO and wild type siblings, although they
exhibited a greater degree of individual variation in
Ab40 and Ab42 levels that made it more difficult to
detect small differences in the mean values (Figure 5).
The results of significance testing for the different Ab
species in young and old animals are shown in Table 3.
Discussion
To identify novel molecular targets relevant to regula-
tion of Ab levels in the brain, we screened viable mouse
KO strains for decreased brain Ab40. A total of 1930
different gene ablations giving rise to viable homozygous
mice were evaluated. Two of the strains, PIGZ KO and
QPRT KO, showed an unequivocal increase of Ab40
and Ab42 in the screening samples, whereas changes in
Ab were less obvious for the other KO strains. The two
KO strains showing the lowest values of Ab40 and Ab42
in the screen, UBE2R2 and ADRM1, were of uncertain
significance given the small number of samples tested.
Given the wide variety of mechanisms and proteins
that have been reported to affect Ab, and the relatively
large number of gene KO strains tested, it was surpris-
ing that we did not identify a single new gene KO strain
that caused a robust (≥50%) decrease in Ab. A combina-
tion of several reasons may account for this. First, the
choice of gene KO strains entering the screen was based
on the ‘druggable genome’, which mostly limited the
KO strains to proteins in gene families known to inter-
act with small molecules. Second, the gene KO strains
entering the screen were limited to those strains that
resulted in viable homozygous adult mice. Approxi-
m a t e l yo n et h i r do ft h eg e n eK Oc o n s t r u c t sm a d ew e r e
homozygous embryonic lethal, and were consequently
not included in the brain Ab screen. Therefore, effective
Ab-lowering targets such as presenilin 1, for which
genetic ablation is deleterious, would not have been
tested in this screen. Third, functional redundancy, e.g.
the genes encoding the Aph1B and Aph1C subunits of
g-secretase [56], could have obscured any effects of sin-
gle gene ablations. There is also the possibility of devel-
opmental compensation, in which alternative pathways
functionally substitute for the missing gene, thus restor-
ing Ab levels in the adult. Fourth, inbred mice have
been shown to express significantly different levels of
brain Ab [57], raising the possibility that genetic
changes in these mice may have obscured the function
of some genes (epistasis). Fifth, there is the possibility
that some genes may affect Ab levels only in older mice,
and therefore the role of these putative genes would not
have been apparent at the age of three months when
our mice were harvested. Sixth the ability of the screen
to detect changes in Ab was limited by the intrinsic
variability in Ab combined with the small group size,
which in most cases was equal to four homozygous KO
animals. This limitation to four animals per KO strain
was necessary because of the resource and time con-
straints of producing and maintaining multiple KO
mouse colonies, and the use of most of the available KO
mice for other phenotypic and biochemical tests not
reported here. Nevertheless the statistical power of the
screen was favorable. Based on the good fit of the data
to the normal distribution (Shapiro-Wilk’st e s tp>
0.05), the false negative error rate (Type II error) was
found to be 1.7% for detection of a KO strain with 50%
lowering of Ab, and 5.99E-9 for a KO strain with 85%
lowering of Ab, as observed in the BACE1 KO samples.
Thus, there was a high probability for detection of any
KO strains robustly lowering Ab.I na d d i t i o n ,t h em o s t
practical Ab-lowering targets should have the potential
to lower Ab by a robust and substantial amount, and
thus, for the purpose of identifying the most practical
targets, a low group size could be tolerated. The false
positive error rate (Type I error) for a KO strain more
than 3 sd below the mean was 0.13%, and for 10 sd
above the mean was negligible at less than 6.7E-16.
Thus, the results for the two KO strains, UBE2R2 and
ADRM1, which exhibited the lowest brain Ab levels
around three standard deviations below the mean, could
have been due to chance, whereas the Ab increases in
the PIGZ and QPRT KO strains were very unlikely due
to chance. Finally, despite the possible limitations
Table 1 Summary of genes by class
Gene class Number
Ion channel 85
DNA enzyme 9
Enzyme 307
G-Protein coupled receptor 89
Inhibitor 23
Kinase 193
Membrane and secreted 109
Membrane 304
Miscellaneous 40
Nuclear hormone receptor 4
Phosphodiesterase 18
Phosphatase 36
Protease 143
Putative secreted 57
Receptor associated protein 1
Secreted 317
Signaling 11
Cytoskeletal 2
Transporter 175
Transcription factor 3
Total 1926
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Page 4 of 12Figure 2 Primary screen of Ab40 levels. Panel A - The median values of Ab40 relative to baseline for each of 1930 KO strains is shown in red.
Assay plate values for BACE1, BACE2 double KO brains are shown in blue, and values for Ab1-14 synthetic peptide-blocked wild type brains are
shown in green. The results for the PIGZ KO and the QPRT KO are indicated by arrows. Panel B - Same as panel A, except mean values of Ab40
are plotted.
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molecular targets capable of robust Ab lowering in the
relevant context of brain are rare.
Brain Ab40, Ab42 and Ab1-x levels in GPR3 KO mice
were evaluated more thoroughly by using a larger num-
ber of mice. No changes in brain Ab42, Ab40 or Ab1-x
were detected in sagittal brain halves from these mice.
This contrasts with the results reported by Thathiah
et al. [26] in which ca. 50% lowering of Ab40 and Ab42
was observed in APP-transgenic GPR3 KO mice. There
are two noteworthy experimental differences between
the two studies, first, we assayed endogenous mouse Ab,
not transgenic human Ab, and second, we used sagittal
brain halves not hippocampal sections. Unfortunately,
our analysis did not extend to hippocampal sections,
which constitutes only a small fraction of total brain.
GPR3 is expressed at high levels in the cortex, which,
like hippocampus, is relevant to AD. Thus, evaluation of
Ab in the hippocampus of non-APP GPR3 KO and in
the cortex and/or whole brain of APP transgenic GPR3
KO would be interesting.
Two gene ablations, corresponding to the PIGZ and
QPRT enzymes, exhibited significantly increased Ab40
and Ab42 in the screening samples. While further sub-
stantiation of the results for PIGZ and QPRT using lar-
ger groups of homozygous KO mice is clearly desirable,
plausible molecular mechanisms for increased Ab can
be proposed. PIGZ, also known as SMP3, is a mannosyl
transferase that catalyses addition of a fourth side chain
mannose to the glycosylphosphatidylinositol (GPI) pro-
tein anchor precursor [58,59]. In cell cultures, GPI
anchored proteins are necessary for Ab synthesis [20],
and targeting of an artificial BACE1-GPI chimera to
lipid rafts greatly increases Ab production [22], although
targeting of BACE1 to lipid rafts is not necessary for Ab
s y n t h e s i s[ 6 0 ] .T h u s ,i nc e l lc u l t u r e ,ac o n n e c t i o n
between GPI anchor metabolism and Ab levels is well
established. An effect of PIGZ on brain Ab would
extend these conclusions to a relevant organ in vivo,
and further raises the possibility that the fourth man-
n o s er e s i d u ep l a y sas p e c i f i cr o l ei nA b metabolism.
QPRT is the enzyme responsible for quinolinic acid
turnover in the kynurenine pathway of tryptophan
Figure 3 Ab levels in left and right brain halves of selected KO
strains. Panel A - Median values of Ab40 in right brain halves were
plotted against median values in left brain halves. An ellipse
highlights the results for UBE2R2 and ADRM1. The results for the
PIGZ KO and the QPRT KO are indicated by arrows. Panel B - Same
as panel A, except that mean Ab values were plotted. Panel C -
Relative values of Ab40 and Ab42 from left and right brain halves in
individual animals is shown for four named KO strains. Note that left
and right are not directly comparable because different extraction
and assays procedures were used (see Methods). Bars represent the
mean value.
Table 2 Paired t-tests conducted on UBE2R2, ADRM1,
PIGZ and QPRT KO strains
Left vs. right
comparisons
Mean
difference
t-value (degrees
of freedom)
P-value
UBE2R2 KO 15.44 2.40 (3) 0.0957
ADRM1 KO 1.64 0.24 (3) 0.8286
PIGZ KO -177 -2.48 (3) 0.0894
QPRT KO 58.64 0.72 (3) 0.5229
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would be expected to increase quinolinic acid levels.
Increased quinolinic acid has been reported in AD brain
[62,63], and treatment of primary neuronal cultures with
quinolinic acid has been reported to increase cell death
and oxidative stress [64]. The association of oxidative
stress with increased BACE1 activity and Ab production
has been widely substantiated in AD [10,15,65-69], rais-
ing the possibility of a mechanistic connection between
quinolinic acid and Ab through activation of BACE1 by
oxidative stress. In addition, quinolinic acid has been
reported to increase APP expression in rat brain, which
could contribute to increased Ab production [70].
The two KO strains for which the lowest values of
Ab40 and Ab42 (ca. 30% lowering) were observed in our
screen corresponded to the UPS proteins Adrm1 and
Ube2R2. Adrm1, also known as hRpn13, associates with
the proteasome 19S regulatory particle, and is required
for recruitment of the Uch37 deubiquitinating enzyme to
the proteasome [71,72]. Ube2R2 (sequence NM-017811)
is a ubiquitin conjugating enzyme. Decreased expression
of several other ubiquitin conjugating enzymes has been
reported to decrease Ab production in cell culture [73].
The UPS has multiple potential roles in AD in addition
to possible regulation of Ab levels, as recently reviewed
in detail by Upadhya and Hegde [74]. Possible mechan-
isms of proteasomal regulation of Ab include resveratrol-
activated clearance of Ab [55], and competition with
g-secretase for APP processing [27]. Thus, an intriguing
possibility is that selective inhibition of specific sub-
pathways of the UPS might decrease brain Ab levels by
both biosynthetic and clearance mechanisms. However,
from a drug discovery perspective, this would carry the
risk of further exacerbating the already defective protea-
some activity prevalent in AD thought to result from the
accumulation of toxic Ab and tau aggregates. Further-
more, assuming that maximal inhibition of Adrm1 or
Ube2R2 would elicit only a 30% decrease in brain Ab,
even the effect of an inhibitor with ideal drug properties
would be limited, and the expected small changes in Ab
difficult to quantify.
Conclusions
Gene ablations that have a robust effect on brain Ab
appear to be rare, at a rate of approximately one in a
thousand of the genes reported here. However, several
pathways including GPI anchor metabolism, the kynure-
nine pathway of tryptophan degradation, and the UPS
may be worth further evaluation for their roles in brain
Ab regulation.
Figure 4 Effect of GPR3 KO on brain Ab levels in young mice.
Panel A - Ab42 was assayed in brain extracts from ten GPR3 wild
type (GPR3+/+), ten heterozygous (GPR3+/-), and ten homozygous
GPR3 KO (GPR3-/-) mice. Brain Ab42 was also determined in BACE1,
BACE2 homozygous double KO (B1/2 dKO) and wild type (BACE+/+)
control mice. Bars represent the mean values. Panel B - the same
brain extracts were assayed for Ab40. Panel C - the same brain
extracts were assayed for Ab1-x.
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Mouse KO strains and brain samples
Experimental procedures with mice were authorized by,
and in compliance with, the Lexicon Pharmaceuticals
Animal Care and Use Committee, and the Bristol-Myers
Squibb Animal Care and Use Committee. The BACE1,
BACE2 and GPR3 KO strains were provided by Lexicon
Pharmaceuticals under the terms of the LexVision®
Database and Collaboration Agreement. The BACE1/
BACE2 double KO obtained by intercrossing the BACE1
and BACE2 KO strains has been described previously
[75]. The GPR3 KO was made by targeted homologous
recombination in mouse strain 129SvEv
Brd-derived
embryonic stem cells, using a targeting construct con-
taining a bGeo/puromycin selection cassette to remove
1,023 nucleotides encompassing the entire amino acid
coding region in the single exon of this gene (see NCBI
nucleotide reference sequence NM_008154 for GPR3).
Recombination in ES cells was confirmed by Southern
analysis. Chimeric mice were bred with C57BL/6J albino
mice to generate F1 heterozygous animals. The F1 mice
were intercrossed, and the genotypes of F2 progeny
Figure 5 Effect of GPR3 KO on brain Ab levels in aged mice.A b40 and Ab42 were determined in one year aged mice for 13 GPR3 wild type
(G3+/+) and 13 homozygous GPR3 KO (G3-/-) mice. For comparison, Ab40 and Ab42 for five young wild type (B1/2+/+) and four young BACE1,
BACE2 homozygous double KO (B1/2 dKO) are shown. Values are expressed as percentage of mean value in the GPR3 wild type mice. One
individual GPR3 wild type mouse with a value of 624% was excluded from the analysis.
Table 3 Comparisons between GPR3 KO and wild type animals using independent samples t-tests
Comparisons Mean Difference t-value (degrees of freedom) P-value
Ab40 young -/- vs +/+ -7.69 -1.76 (18) 0.0955
Ab40 young +/- vs +/+ -6.99 -1.71 (18) 0.1051
Ab42 young -/- vs +/+ -1.21 -1.37 (18) 0.1890
Ab42 young +/- vs +/+ -0.22 -0.34 (18) 0.7374
Ab1-x young -/- vs +/+ -6.70 -0.82 (18) 0.4211
Ab1-x young +/- vs +/+ 13.34 1.90 (18) 0.0737
Ab40 old -/- vs +/+ -51.56 -1.17 (24) 0.2519
Ab42 old -/- vs +/+ -9.55 -0.86 (24) 0.3998
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genotype frequencies, 20 wild type, 33 heterozygous and
15 homozygous mice, were not significantly different
from the Mendelian segregation ratios expected for a
viable allele. The genotypes of further F2 progeny were
determined by PCR of tail or ear DNA using the DNA
primer 5’-GAATTAAGCCCTGGTGGACCTA, corre-
sponding to sequence adjacent to the GPR3 deletion, in
combination with the primer 5’-GTTGCCCTTCACTGT
CTACTGC, corresponding to deleted GPR3 sequence,
to detect a 286 nucleotide product from the wild type
GPR3 allele, or in combination with the primer 5’-
GCAGCGCATCGCCTTCTATC, derived from the neo
marker gene, to detect a 208 nucleotide product from
the GPR3 KO allele. For the GPR3 KO studies, animals
were either 3 months old ‘young’ or 1 year old ‘aged’ at
t h et i m eo fh a r v e s t i n g .T h eo t h e r1 9 3 0K Os t r a i n s ,c o r -
responding to 1926 different genes, including the PIGZ,
QPRT, and ADRM1 KO strains derived from the Omni-
Bank® gene trap library, and the UBE2R2 KO strain
made by targeted homologous recombination, were
made by Lexicon Pharmaceuticals as part of its Gen-
ome5000™ program [76]. A summary of the 1926 genes
by gene class is shown in Table 1.
Preparation and storage of brain samples
For the primary screen of brain Ab levels, four mice
from each KO strain were euthanized at three months
o fa g eb yC O 2 asphyxiation and sagittal brain halves
lacking cerebellum were frozen and stored at -80°C.
Samples were shipped on dry ice from Lexicon Pharma-
ceuticals to Bristol-Myers Squibb as they became avail-
able over a period of four years. Because the availability
of individual mice occurred with varied timing, and
because multiple different KO strains were in produc-
tion simultaneously, the order of acquisition of brain
samples was variable. This resulted in the four samples
from any given KO strain arriving at different times,
and thus the Ab ELISA being carried out usually on dif-
ferent assay plates and different assay dates for each
sample of a given KO strain. The Ab primary screen
values obtained even for a given gene KO therefore
represented essentially all of the sources of variability to
which the data were subject.
Ab sample preparation and ELISA assays
The assay used for the primary screen of all brain sam-
ples has been partly described previously [75]. Frozen
left brain halves were thawed and homogenized at a
concentration of 4 ml/g in ice cold 2% CHAPS, 20 mM
Tris-Cl pH 7.7, in the presence of complete protease
inhibitor cocktail (Roche Diagnostics, Mannheim,
Germany). Homogenization was carried out by agitation
in 2.0 ml polypropylene tubes containing a steel bead
(5 mm diameter) for 4 min. at maximum power using
the TissueLyzer (Qiagen). Homogenates were centri-
fuged at 21,000 × g at 4°C for 30 min. Supernatant from
the centrifugation was stored frozen at -80°C, and
thawed immediately before use in the ELISA. ELISA to
quantify Ab was carried out in 96-well format using
three wells per sample. The capture antibody was the
Ab40 C-terminal end-specific monoclonal antibody
TSD9S3.2 (Bristol-Myers Squibb), and detection was
carried out using peroxidase conjugated monoclonal
antibody 252Q6 (Invitrogen), specific for the N-terminal
region of mouse Ab.T oc o n f i r mr e s u l t sf o rs e l e c t e d
brain samples, the corresponding frozen right brain
halves were thawed and homogenized in CHAPS buffer
for assay of Ab40, as described above. Alternatively,
right brain halves were homogenized at a concentration
of 10 ml/g in 6M guanidine by agitation with a steel
bead, as described above, centrifuged at 21,000 × g at 4°
C for 60 min., and Ab was concentrated from the super-
natant by solid phase extraction using Oasis HLB car-
tridges (Waters) on a vacuum manifold as described
[77]. Eluates in methanol/0.1% NH4OH containing Ab
from the solid phase extraction were dried in a rotary
evaporator under vacuum and resuspended in phosphate
buffered saline pH 7.4 containing 0.1% bovine serum
albumin (Sigma cat. #A7030) and 0.1% Triton X-100
immediately before use in ELISA. Ab40 was quantified
by ELISA in triplicate wells as described above, and
Ab42 was quantified by ELISA using the monoclonal
252Q6 (Invitrogen) as capture antibody, and Ab42 C-
terminal end-specific monoclonal 565 peroxidase conju-
gate (Bristol-Myers Squibb) as the detection antibody.
To monitor assay performance, the first 109 assay plates
contained control wells of wild type and BACE dKO
extracts. The value of z’ ranged from 0.5 to 0.74 for
these first plates, indicating that any samples containing
decreased Ab should be readily detectable [78]. To
monitor assay performance without the need for BACE
dKO animals, subsequent plates contained wild type
extract control wells in which the detecting antibody
incubation contained rat Ab1-14 synthetic peptide (Ana-
spec) at a concentration of 1 μg/ml. All reagents, unless
otherwise stated, were obtained from Sigma. The guani-
dine/solid phase extraction method, as described above,
was also used for determination of Ab42 and Ab40 in
the aged GPR3 KO study. For the young GPR3 KO ani-
mals, brain samples were homogenized in 0.2% dietha-
nolamine, 50 mM NaCl and protease inhibitor cocktail
(Roche) for Ab42 and Ab40 ELISAs as described above.
The Ab1-x assay utilized the combination of monoclo-
nals 252Q6 and 4G8 (Covance). Assay results were cali-
brated using synthetic Ab42 or Ab40 peptides (Anaspec)
and expressed as average pM concentration present in
brain tissue prior to homogenization.
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Page 9 of 12Evaluation of Ab results
To maintain consistency in the Ab40 determinations
between assay plates, the baseline value of Ab40 was
set equal to the mean value of all wells containing
brain samples, excluding the BACE1/2 double KO or
Ab1-14 inhibited wells. Thus, the plate baseline gener-
ally depended on the mean value of 72 wells per plate.
Alternative baseline values determined from known
concentrations of synthetic Ab40 peptides, or deter-
mined from pools of brain extracts from wild type
mice, were found to be less consistent over time, and
were therefore not used for evaluation of Ab40 base-
line levels. Median values of Ab40 were calculated to
avoid the potentially disproportionate effect of unu-
sually high or low individual samples that could occur
if using mean values, however, in the final analysis, use
of mean or median values yielded the same outcome.
Initially, calculations were carried out using data from
a limited number of KO strains, and therefore some
initial follow up assays were carried out for KO strains
for which the median Ab40 value was less than 2 sd
from baseline.
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